G. Jeyakumar

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

A. Rosenwald, H. Kantarjian, Xuelin Huang, 2014, The Lancet. Oncology.

Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

E. Heath, J. Fontana, U. Vaishampayan, 2017, Journal of Immunotherapy for Cancer.

New Therapeutic Advances in Chronic Lymphocytic Leukemia

Aless, G. Jeyakumar, ra Ferrajoli, 2014 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014, Leukemia research.

Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

H. Kantarjian, Xuelin Huang, M. Keating, 2013 .